Kamran Balighi

2.7k total citations
158 papers, 1.7k citations indexed

About

Kamran Balighi is a scholar working on Pathology and Forensic Medicine, Genetics and Dermatology. According to data from OpenAlex, Kamran Balighi has authored 158 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Pathology and Forensic Medicine, 53 papers in Genetics and 48 papers in Dermatology. Recurrent topics in Kamran Balighi's work include Autoimmune Bullous Skin Diseases (95 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (51 papers) and Urticaria and Related Conditions (36 papers). Kamran Balighi is often cited by papers focused on Autoimmune Bullous Skin Diseases (95 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (51 papers) and Urticaria and Related Conditions (36 papers). Kamran Balighi collaborates with scholars based in Iran, United States and Australia. Kamran Balighi's co-authors include Maryam Daneshpazhooh, Hamidreza Mahmoudi, Cheyda Chams‐Davatchi, Soheil Tavakolpour, Zahra Hallaji, Nafiseh Esmaili, Mahin Valikhani, Robabeh Abedini, Zeinab Aryanian and Parvaneh Hatami and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Kamran Balighi

135 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kamran Balighi Iran 23 1.1k 715 641 446 246 158 1.7k
Agustı́n España Spain 25 684 0.6× 455 0.6× 507 0.8× 589 1.3× 140 0.6× 108 1.8k
Arti Nanda Kuwait 23 470 0.4× 182 0.3× 280 0.4× 487 1.1× 93 0.4× 88 1.6k
Jean-Marie Bonnetblanc France 19 587 0.5× 382 0.5× 513 0.8× 261 0.6× 113 0.5× 65 1.2k
Lynne Morrison United States 15 459 0.4× 235 0.3× 246 0.4× 207 0.5× 65 0.3× 28 798
O. De Pità Italy 19 354 0.3× 107 0.1× 255 0.4× 412 0.9× 44 0.2× 48 1.1k
Richard P. Kaplan United States 18 381 0.3× 154 0.2× 225 0.4× 220 0.5× 59 0.2× 33 818
Charles Perniciaro United States 21 428 0.4× 125 0.2× 311 0.5× 649 1.5× 68 0.3× 45 1.2k
Catherine McCuaïg Canada 29 722 0.7× 100 0.1× 186 0.3× 333 0.7× 52 0.2× 89 2.4k
R. D. G. Peachey United Kingdom 19 380 0.3× 103 0.1× 282 0.4× 450 1.0× 30 0.1× 61 1.2k
J.R. Hughes United Kingdom 12 219 0.2× 113 0.2× 146 0.2× 333 0.7× 23 0.1× 24 785

Countries citing papers authored by Kamran Balighi

Since Specialization
Citations

This map shows the geographic impact of Kamran Balighi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamran Balighi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamran Balighi more than expected).

Fields of papers citing papers by Kamran Balighi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamran Balighi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamran Balighi. The network helps show where Kamran Balighi may publish in the future.

Co-authorship network of co-authors of Kamran Balighi

This figure shows the co-authorship network connecting the top 25 collaborators of Kamran Balighi. A scholar is included among the top collaborators of Kamran Balighi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamran Balighi. Kamran Balighi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Balighi, Kamran, et al.. (2024). Analysis of Hospitalization Cases for Filler Injection Complications: A Five‐Year Retrospective Study Among Iranian People. Journal of Cosmetic Dermatology. 24(2). e16733–e16733.
2.
Kamyab, Kambiz, et al.. (2024). A case of IgA pemphigus, with a poor response to dapsone, successfully treated with adalimumab. SHILAP Revista de lepidopterología. 12(5). e8807–e8807.
3.
Balighi, Kamran, et al.. (2023). A case report of esophageal cancer in a patient with pemphigus vulgaris: A coincidence or something beyond that?. Cancer Reports. 6(12). e1896–e1896. 1 indexed citations
4.
Aryanian, Zeinab, et al.. (2023). The impact of the COVID‐19 pandemic on the diagnosis and treatment of skin cancers, a mini review. Cancer Reports. 6(9). e1854–e1854. 3 indexed citations
5.
Hatami, Parvaneh, et al.. (2023). Isotretinoin and timing of procedural interventions: Clinical implications and practical points. Journal of Cosmetic Dermatology. 22(8). 2146–2149. 2 indexed citations
6.
Aryanian, Zeinab, Kamran Balighi, Seyed Naser Emadi, & Parvaneh Hatami. (2023). Rituximab as a maintenance treatment in patients with pemphigus vulgaris: When is the right time for discontinuation?. Journal of Cosmetic Dermatology. 23(2). 406–408.
7.
Aryanian, Zeinab, et al.. (2023). Various aspects of the relationship between vitiligo and theCOVID‐19 pandemic orSARS‐CoV‐2 vaccines: Clinical pearls for dermatologists. Journal of Cosmetic Dermatology. 22(4). 1152–1156. 4 indexed citations
8.
Balighi, Kamran, et al.. (2023). Kaposi's sarcoma in a patient with pemphigus vulgaris mimicking exacerbation of pemphigus. Cancer Reports. 6(5). e1815–e1815. 2 indexed citations
9.
Daneshpazhooh, Maryam, et al.. (2023). Treatment Resistance to TNF‐α Inhibitors in Patients with Psoriasis. Dermatologic Therapy. 2023(1).
10.
Balighi, Kamran, et al.. (2022). Factors associated with the healing time of pemphigus vulgaris oral lesions: A prospective study. Oral Diseases. 29(5). 2248–2255. 4 indexed citations
11.
Hatami, Parvaneh, et al.. (2022). Serious health threat of mucormycosis during the ongoing COVID‐19 pandemic: what dermatologists need to know in this regard. International Journal of Dermatology. 61(8). 979–981. 7 indexed citations
13.
Mahmoudi, Hamidreza, et al.. (2020). Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatologic Therapy. 34(1). e14633–e14633. 13 indexed citations
14.
Mahmoudi, Hamidreza, et al.. (2019). Single‐nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine. International Journal of Immunogenetics. 47(1). 41–49. 15 indexed citations
15.
Daneshpazhooh, Maryam, Mahmoud Djalali, Hamed Mohammadi, et al.. (2019). Effects of l ‐carnitine supplementation on cardiovascular and bone turnover markers in patients with pemphigus vulgaris under corticosteroids treatment: A randomized, double‐blind, controlled trial. Dermatologic Therapy. 32(5). e13049–e13049. 8 indexed citations
16.
Ghanadan, Alireza, et al.. (2019). Immunohistochemical Staining in the Assessment of Melanoma Tumor Thickness. Pathology & Oncology Research. 26(2). 885–891. 6 indexed citations
17.
Daneshpazhooh, Maryam, Hamidreza Mahmoudi, Kamran Balighi, et al.. (2018). Comparison of ethylenediaminetetraacetic acid-treated desmoglein ELISA and conventional desmoglein ELISA in the evaluation of pemphigus vulgaris in remission. Journal of the American Academy of Dermatology. 79(4). 768–770. 4 indexed citations
18.
Ghiasi, Maryam, et al.. (2017). Adverse reactions associated with intravenous immunoglobulin therapy in patients with dermatologic diseases: An 11-year retrospective study. 20(1). 6–10. 1 indexed citations
19.
Balighi, Kamran, et al.. (2013). Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. International Journal of Dermatology. 52(7). 862–867. 33 indexed citations
20.
Nejatisafa, Ali‐Akbar, et al.. (2008). Psychiatric Characteristics and Quality of Life in Patients with Pathologic Skin Picking. SHILAP Revista de lepidopterología. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026